## Gene Summary
IRS1 (Insulin Receptor Substrate 1) is a key signaling molecule in the insulin and IGF-1 (insulin-like growth factor) pathways. It mediates the effects of insulin and IGF-1 by acting as an adapter protein that facilitates downstream signaling after being phosphorylated by activated insulin and IGF-1 receptors. IRS1 plays a crucial role in the control of cellular growth, glucose homeostasis, and lipid metabolism. It is predominantly expressed in tissues that are primary targets for insulin action, like liver, muscle, and adipose tissue.

## Gene Drugs, Diseases, Phenotypes, and Pathways
IRS1 is implicated in several pathways that regulate cell growth, differentiation, survival, and metabolism, predominantly influenced by insulin and IGF-1 signaling. Dysregulation or genetic variation of IRS1 can contribute to conditions such as diabetes (particularly type 2 diabetes), obesity, and growth disorders. Its role in metabolic signaling also links IRS1 to syndromes characterized by insulin resistance. Research indicates that IRS1 interacts with multiple genes and proteins which play roles in metabolic disease pathways, implicating a broad reach in its potential effect on various metabolic phenotypes.

## Pharmacogenetics
In pharmacogenetics, IRS1 variants are studied primarily for their associations with the efficacy of drugs targeting metabolic disorders and their complications. For example, polymorphisms in IRS1 have been linked to differential responses to metformin, a first-line medication for type 2 diabetes. Since IRS1 influences insulin signaling, its genetic variations can lead to altered insulin sensitivity, thus affecting how patients respond to insulin therapy and other pharmacologic agents aiming to control glucose levels. Understanding these associations is crucial for tailoring individualized treatment plans in metabolic disorders, especially in determining appropriate drug dosages and combinations.